Vaccine for Prophylaxis or Treatment of an Allergen-Driven Airway Pathology

1 . A vaccine for the prophylaxis or treatment of an allergen-driven airway pathology, said vaccine comprising a live attenuated Bordetella pertussis strain which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT)

2 . The vaccine according to claim 1 , wherein the allergen-driven airway pathology is selected from the group consisting of allergic asthma, Hay fever and interstitial lung diseases.

3 . The vaccine according to claim 1 , wherein the subject is a neonate or an infant.

4 . The vaccine according to claim 1 , wherein the live attenuated Bordetella pertussis vaccine is the BPZE1 strain.

5 . The vaccine according to claim 1 , wherein the live attenuated Bordetella pertussis strain comprises a heterologous antigen.

6 . A live life attenuated Bordetella pertussis vaccine according to claim 1 , wherein the live attenuated Bordetella pertussis vaccine is administered by nasal administration or by inhalation.

7 . The vaccine according to claim 1 , wherein the vaccine comprises an adjuvant and a pharmaceutically acceptable carrier or diluent.

8 . A method of vaccination or treatment of an allergen driven airway pathology in a subject comprising administering to said subject a composition comprising a vaccine of claim 1 .

9 . The method of claim 8 wherein the allergen-driven airway pathology is selected from the group consisting of allergic asthma, Hay fever and interstitial lung diseases.

10 . The method of claim 8 , wherein the subject is a neonate or an infant.

11 . The method of claim 8 , wherein the live attenuated Bordetella pertussis vaccine comprises the BPZE1 strain.

12 . The method of claim 8 , wherein the live attenuated Bordetella pertussis vaccine comprises a heterologous antigen.

13 . The method of claim 8 , wherein the live attenuated Bordetella pertussis vaccine is administered by nasal administration or by inhalation.

14 . A method for the preparation of a vaccine for the prophylaxis or treatment of an allergen-driven airway pathology comprising preparing a live Bordetella pertussis strain which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) and admixing said Bordetella pertussis strain with and adjuvant and/or a pharmaceutically acceptable carrier or diluent for nasal or inhalational administration.

15 . The method of claim 14 wherein the allergen-driven airway pathology is selected from the group consisting of allergic asthma, Hay fever and interstitial lung diseases.

16 . The method of claim 14 , wherein the live attenuated Bordetella pertussis vaccine comprises the BPZE1 strain and optionally, wherein the live attenuated Bordetella pertussis vaccine comprises a heterologous antigen.

17 . A method of protecting a subject from an allergen-driven airway pathology comprising administering to said subject a vaccine comprising a live Bordetella pertussis strain which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) in an amount effective to vaccinate against said allergen-driven airway pathology.

18 . The method of claim 17 wherein the allergen-driven airway pathology is selected from the group consisting of allergic asthma, Hay fever and interstitial lung diseases.

19 . The method of claim 17 , wherein the live attenuated Bordetella pertussis vaccine comprises the BPZE1 strain and optionally, wherein the live attenuated Bordetella pertussis vaccine comprises a heterologous antigen.